![](https://www.lachmanconsultants.com/wp-content/uploads/2019/01/iStock-1026998982.jpg)
FDA Draft Guidance – Notice of Marketing Status of NDAs and ANDAs
The Drug Price Competition and Patent Term Restoration Act of 1984 requires the FDA to publish a notice of all approved products and their marketing status. The FDA satisfies this requirement by publication of the drug products in the Orange Book; the FDA will publish information in the active section (if the product is currently […]